Atopic dermatitis: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
S.Singh (talk | contribs)
772 edits
S.Singh (talk | contribs)
772 edits
Line 24: Line 24:
Atopic dermatitis is a chronic inflammatory skin disorder with an immunologic background and occurs in patients with a personal or family history of atopy (i.e., asthma or allergic rhinitis).<ref name="MihmSoter1976">{{cite journal|last1=Mihm|first1=Martin C|last2=Soter|first2=Nicholas A|last3=Dvorak|first3=Harold F|last4=Austen|first4=K Frank|title=The Structure Of Normal Skin And The Morphology Of Atopic Eczema|journal=Journal of Investigative Dermatology|volume=67|issue=3|year=1976|pages=305–312|issn=0022202X|doi=10.1111/1523-1747.ep12514346}}</ref> It is caused by either skin barrier dysfunction or immune dysregulation of the adaptive and innate immune response leading to an enhanced IgE-mediated, systemic Th2 response. The skin barrier is invaded by exogenous substances, including allergens, irritants and microbes; and brick wall-like’ structure of the stratum corneum is further compromised. Systemically, a dysfunctional innate and adaptive immune response causes further damage to the epidermis<ref name="pmid20109730">{{cite journal |vauthors=Barnes KC |title=An update on the genetics of atopic dermatitis: scratching the surface in 2009 |journal=J. Allergy Clin. Immunol. |volume=125 |issue=1 |pages=16–29.e1–11; quiz 30–1 |date=January 2010 |pmid=20109730 |pmc=2874322 |doi=10.1016/j.jaci.2009.11.008 |url=}}</ref>.   
Atopic dermatitis is a chronic inflammatory skin disorder with an immunologic background and occurs in patients with a personal or family history of atopy (i.e., asthma or allergic rhinitis).<ref name="MihmSoter1976">{{cite journal|last1=Mihm|first1=Martin C|last2=Soter|first2=Nicholas A|last3=Dvorak|first3=Harold F|last4=Austen|first4=K Frank|title=The Structure Of Normal Skin And The Morphology Of Atopic Eczema|journal=Journal of Investigative Dermatology|volume=67|issue=3|year=1976|pages=305–312|issn=0022202X|doi=10.1111/1523-1747.ep12514346}}</ref> It is caused by either skin barrier dysfunction or immune dysregulation of the adaptive and innate immune response leading to an enhanced IgE-mediated, systemic Th2 response. The skin barrier is invaded by exogenous substances, including allergens, irritants and microbes; and brick wall-like’ structure of the stratum corneum is further compromised. Systemically, a dysfunctional innate and adaptive immune response causes further damage to the epidermis<ref name="pmid20109730">{{cite journal |vauthors=Barnes KC |title=An update on the genetics of atopic dermatitis: scratching the surface in 2009 |journal=J. Allergy Clin. Immunol. |volume=125 |issue=1 |pages=16–29.e1–11; quiz 30–1 |date=January 2010 |pmid=20109730 |pmc=2874322 |doi=10.1016/j.jaci.2009.11.008 |url=}}</ref>.   


==Pathogenesis==
==[[Atopic dermatitis pathophysiology|Pathophysiology]]==


It is understood that atopic dermatitis is the result of either skin barrier dysfunction or by immune dysregulation.<ref name="pmid21682749">{{cite journal |vauthors=Boguniewicz M, Leung DY |title=Atopic dermatitis: a disease of altered skin barrier and immune dysregulation |journal=Immunol. Rev. |volume=242 |issue=1 |pages=233–46 |date=July 2011 |pmid=21682749 |pmc=3122139 |doi=10.1111/j.1600-065X.2011.01027.x |url=}}</ref>
'''Epidermal barrier dysfunction(outside-in hypothesis):'''<ref name="pmid183290874">{{cite journal |vauthors=Elias PM, Hatano Y, Williams ML |title=Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms |journal=J. Allergy Clin. Immunol. |volume=121 |issue=6 |pages=1337–43 |date=June 2008 |pmid=18329087 |pmc=2706021 |doi=10.1016/j.jaci.2008.01.022 |url=}}</ref>
* The major factors to abnormal skin barrier include loss-of-function mutations in the filaggrin gene (FLG) causing Filaggrin deficiency<ref name="pmid19720210">{{cite journal |vauthors=Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY |title=Cytokine modulation of atopic dermatitis filaggrin skin expression |journal=J. Allergy Clin. Immunol. |volume=124 |issue=3 Suppl 2 |pages=R7–R12 |date=September 2009 |pmid=19720210 |doi=10.1016/j.jaci.2009.07.012 |url=}}</ref>, tight junction abnormalities<ref name="pmid21163515">{{cite journal |vauthors=De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA |title=Tight junction defects in patients with atopic dermatitis |journal=J. Allergy Clin. Immunol. |volume=127 |issue=3 |pages=773–86.e1–7 |date=March 2011 |pmid=21163515 |pmc=3049863 |doi=10.1016/j.jaci.2010.10.018 |url=}}</ref>, more alkaline surface pH,<ref name="pmid18329087">{{cite journal |vauthors=Elias PM, Hatano Y, Williams ML |title=Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms |journal=J. Allergy Clin. Immunol. |volume=121 |issue=6 |pages=1337–43 |date=June 2008 |pmid=18329087 |pmc=2706021 |doi=10.1016/j.jaci.2008.01.022 |url=}}</ref> microbial colonization, altered protease activity in the stratum corneum.<ref name="pmid16815133">{{cite journal |vauthors=Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R |title=New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions |journal=J. Allergy Clin. Immunol. |volume=118 |issue=1 |pages=3–21; quiz 22–3 |date=July 2006 |pmid=16815133 |doi=10.1016/j.jaci.2006.04.042 |url=}}</ref><ref name="pmid23374260">{{cite journal |vauthors=McAleer MA, Irvine AD |title=The multifunctional role of filaggrin in allergic skin disease |journal=J. Allergy Clin. Immunol. |volume=131 |issue=2 |pages=280–91 |date=February 2013 |pmid=23374260 |doi=10.1016/j.jaci.2012.12.668 |url=}}</ref><ref name="pmid22951058">{{cite journal |vauthors=Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, Sandilands A, McLean WH, Rebbeck TR, Mitra N |title=The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort |journal=J. Allergy Clin. Immunol. |volume=130 |issue=4 |pages=912–7 |date=October 2012 |pmid=22951058 |pmc=3462287 |doi=10.1016/j.jaci.2012.07.008 |url=}}</ref><ref name="pmid22521249">{{cite journal |vauthors=Morizane S, Yamasaki K, Kajita A, Ikeda K, Zhan M, Aoyama Y, Gallo RL, Iwatsuki K |title=TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis |journal=J. Allergy Clin. Immunol. |volume=130 |issue=1 |pages=259–61.e1 |date=July 2012 |pmid=22521249 |pmc=3387356 |doi=10.1016/j.jaci.2012.03.006 |url=}}</ref>
* Skin barrier abnormalities lead to the permeability of epidermis, causing entry of antigens or pathogens, microbial colonization most notably by ''Staphylococcus aureus'' and herpes simplex virus (HSV); leading to the production of inflammatory cytokines and Impaired production of antimicrobial peptides.<ref name="pmid23712284">{{cite journal |vauthors=Leung DY |title=New insights into atopic dermatitis: role of skin barrier and immune dysregulation |journal=Allergol Int |volume=62 |issue=2 |pages=151–61 |date=June 2013 |pmid=23712284 |doi=10.2332/allergolint.13-RAI-0564 |url=}}</ref>
* Skin barrier abnormalities also leads to increased trans-epidermal water loss, and decreased levels of ceramides and water binding.<ref name="pmid19494826">{{cite journal| author=Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M et al.| title=Epidermal barrier dysfunction in atopic dermatitis. | journal=J Invest Dermatol | year= 2009 | volume= 129 | issue= 8 | pages= 1892-908 | pmid=19494826 | doi=10.1038/jid.2009.133 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19494826  }} </ref>
* Severe atopic dermatitis has been associated with higher levels of trans-epidermal water loss.<ref name="pmid21137118">{{cite journal |vauthors=Flohr C, England K, Radulovic S, McLean WH, Campbel LE, Barker J, Perkin M, Lack G |title=Filaggrin loss-of-function mutations are associated with  early-onset eczema, eczema severity and transepidermal  water loss at 3 months of age |journal=Br. J. Dermatol. |volume=163 |issue=6 |pages=1333–6 |date=December 2010 |pmid=21137118 |doi= |url=}}</ref>
'''Immune dysregulation (inside-out’ hypothesis):'''<ref name="pmid183290872">{{cite journal |vauthors=Elias PM, Hatano Y, Williams ML |title=Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms |journal=J. Allergy Clin. Immunol. |volume=121 |issue=6 |pages=1337–43 |date=June 2008 |pmid=18329087 |pmc=2706021 |doi=10.1016/j.jaci.2008.01.022 |url=}}</ref>:
* '''Innate immune response:'''
**Pathogens or tissue damage activate pattern recognition receptors including Toll-like receptors (TLRs), induce a release of inflammatory mediators, including AMPs, cytokines, and chemokines<ref name="pmid23223142">{{cite journal |vauthors=Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, Gallo RL, Borkowski AW, Yamasaki K, Leung DY, Georas SN, De Benedetto A, Beck LA |title=Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair |journal=J. Invest. Dermatol. |volume=133 |issue=4 |pages=988–98 |date=April 2013 |pmid=23223142 |pmc=3600383 |doi=10.1038/jid.2012.437 |url=}}</ref>
**Defective cutaneous innate immune-mediated epidermal barrier repair and maintenance may alter skin-resident normal microbial flora and lead to severe inflammation as demonstrated with atopic dermatitis patients colonized with ''Staphylococcus aureus''<ref name="pmid22310478">{{cite journal |vauthors=Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA |title=Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis |journal=Genome Res. |volume=22 |issue=5 |pages=850–9 |date=May 2012 |pmid=22310478 |pmc=3337431 |doi=10.1101/gr.131029.111 |url=}}</ref>
**In intact skin barrier, antimicrobial peptides(AMPs) are regulated by cytokines, IL-17, and IL- 22, which are secreted by Th17 T and Th22 cells. This effect is suppressed in patients with atopic dermatitis.<ref name="pmid21315950">{{cite journal |vauthors=Macias ES, Pereira FA, Rietkerk W, Safai B |title=Superantigens in dermatology |journal=J. Am. Acad. Dermatol. |volume=64 |issue=3 |pages=455–72; quiz 473–4 |date=March 2011 |pmid=21315950 |doi=10.1016/j.jaad.2010.03.044 |url=}}</ref>
* '''Adaptive immune response:'''
**Increased allergen penetration through the damaged epidermis leading to a Th2-type milieu is thought to explain the critical link between the barrier defect of atopic dermatitis patients with FLG mutations and Th2 polarization<ref name="pmid216827492">{{cite journal |vauthors=Boguniewicz M, Leung DY |title=Atopic dermatitis: a disease of altered skin barrier and immune dysregulation |journal=Immunol. Rev. |volume=242 |issue=1 |pages=233–46 |date=July 2011 |pmid=21682749 |pmc=3122139 |doi=10.1111/j.1600-065X.2011.01027.x |url=}}</ref>.
**Enhanced expression of Th2, Th17, and Th22 cytokines, characterize the acute initiation of atopic dermatitis lesions<ref name="pmid25282559">{{cite journal |vauthors=Leung DY, Guttman-Yassky E |title=Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches |journal=J. Allergy Clin. Immunol. |volume=134 |issue=4 |pages=769–79 |date=October 2014 |pmid=25282559 |pmc=4186710 |doi=10.1016/j.jaci.2014.08.008 |url=}}</ref>.
**Epidermal barrier function is regulated through Th2 and Th22 cytokines (IL-4, IL-13, IL-31, and IL-22) by:<ref name="pmid252825593">{{cite journal |vauthors=Leung DY, Guttman-Yassky E |title=Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches |journal=J. Allergy Clin. Immunol. |volume=134 |issue=4 |pages=769–79 |date=October 2014 |pmid=25282559 |pmc=4186710 |doi=10.1016/j.jaci.2014.08.008 |url=}}</ref>
***stimulating epidermal hyperplasia
***inhibiting the expression of terminal keratinocyte differentiation genes (eg, ''FLG'', loricrin, involucrin)
***suppressing the production of AMPs
* '''Thymic stromal lymphopoietin:'''
**Defective skin  barrier and enhanced epidermal protease activity, which is reported in atopic dermatitis, promote TSLP production and Th2 response, leading to atopic dermatitis-like inflammation<ref name="pmid222700712">{{cite journal |vauthors=Takai T |title=TSLP expression: cellular sources, triggers, and regulatory mechanisms |journal=Allergol Int |volume=61 |issue=1 |pages=3–17 |date=March 2012 |pmid=22270071 |doi=10.2332/allergolint.11-RAI-0395 |url=}}</ref>.
**''TSLP'' polymorphisms have been linked to the severity of atopic dermatitis.
**TSLP genetic variants are associated with atopic dermatitis and eczema herpeticum.<ref name="pmid20466416">{{cite journal |vauthors=Gao PS, Rafaels NM, Mu D, Hand T, Murray T, Boguniewicz M, Hata T, Schneider L, Hanifin JM, Gallo RL, Gao L, Beaty TH, Beck LA, Leung DY, Barnes KC |title=Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum |journal=J. Allergy Clin. Immunol. |volume=125 |issue=6 |pages=1403–1407.e4 |date=June 2010 |pmid=20466416 |pmc=2925504 |doi=10.1016/j.jaci.2010.03.016 |url=}}</ref>
**In patients with defective skin barrier due to FLG mutations, TSLP genetic variants are associated with reduced probability of having persistent atopic dermatitis<ref name="pmid24401911">{{cite journal |vauthors=Margolis DJ, Kim B, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Mitra N |title=Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis |journal=JAMA Dermatol |volume=150 |issue=3 |pages=254–9 |date=March 2014 |pmid=24401911 |pmc=4414492 |doi=10.1001/jamadermatol.2013.7954 |url=}}</ref>.
== Genetics ==
== Genetics ==
Recent studies have established a strong genetic association with atopic dermatitis. Twin studies have indicated high heritability of atopic dermatitis with a concordance rate of 72–86 % for monozygotic twins compared with 21–23 % percent for dizygotic twins.<ref name="pmid27004062">{{cite journal |vauthors=Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z |title=Molecular Genetic of Atopic dermatitis: An Update |journal=Int J Health Sci (Qassim) |volume=10 |issue=1 |pages=96–120 |date=January 2016 |pmid=27004062 |pmc=4791162 |doi= |url=}}</ref>
Recent studies have established a strong genetic association with atopic dermatitis. Twin studies have indicated high heritability of atopic dermatitis with a concordance rate of 72–86 % for monozygotic twins compared with 21–23 % percent for dizygotic twins.<ref name="pmid27004062">{{cite journal |vauthors=Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z |title=Molecular Genetic of Atopic dermatitis: An Update |journal=Int J Health Sci (Qassim) |volume=10 |issue=1 |pages=96–120 |date=January 2016 |pmid=27004062 |pmc=4791162 |doi= |url=}}</ref>

Revision as of 13:05, 2 October 2018

Atopic dermatitis
Atopic dermatitis
A child with atopic dermatitis

Atopic dermatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atopic dermatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis

CDC on Atopic dermatitis

Atopic dermatitis in the news

Blogs onAtopic dermatitis

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors forAtopic dermatitis

For patient information, click here

WikiDoc Resources for Atopic dermatitis

Articles

Most recent articles on Atopic dermatitis

Most cited articles on Atopic dermatitis

Review articles on Atopic dermatitis

Articles on Atopic dermatitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Atopic dermatitis

Images of Atopic dermatitis

Photos of Atopic dermatitis

Podcasts & MP3s on Atopic dermatitis

Videos on Atopic dermatitis

Evidence Based Medicine

Cochrane Collaboration on Atopic dermatitis

Bandolier on Atopic dermatitis

TRIP on Atopic dermatitis

Clinical Trials

Ongoing Trials on Atopic dermatitis at Clinical Trials.gov

Trial results on Atopic dermatitis

Clinical Trials on Atopic dermatitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Atopic dermatitis

NICE Guidance on Atopic dermatitis

NHS PRODIGY Guidance

FDA on Atopic dermatitis

CDC on Atopic dermatitis

Books

Books on Atopic dermatitis

News

Atopic dermatitis in the news

Be alerted to news on Atopic dermatitis

News trends on Atopic dermatitis

Commentary

Blogs on Atopic dermatitis

Definitions

Definitions of Atopic dermatitis

Patient Resources / Community

Patient resources on Atopic dermatitis

Discussion groups on Atopic dermatitis

Patient Handouts on Atopic dermatitis

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors for Atopic dermatitis

Healthcare Provider Resources

Symptoms of Atopic dermatitis

Causes & Risk Factors for Atopic dermatitis

Diagnostic studies for Atopic dermatitis

Treatment of Atopic dermatitis

Continuing Medical Education (CME)

CME Programs on Atopic dermatitis

International

Atopic dermatitis en Espanol

Atopic dermatitis en Francais

Business

Atopic dermatitis in the Marketplace

Patents on Atopic dermatitis

Experimental / Informatics

List of terms related to Atopic dermatitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Synonyms and keywords: Atopic eczema, Erythrodermic eczema

Overview

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[4]

Overview

Atopic dermatitis is a chronic inflammatory skin disorder with an immunologic background and occurs in patients with a personal or family history of atopy (i.e., asthma or allergic rhinitis).[1] It is caused by either skin barrier dysfunction or immune dysregulation of the adaptive and innate immune response leading to an enhanced IgE-mediated, systemic Th2 response. The skin barrier is invaded by exogenous substances, including allergens, irritants and microbes; and brick wall-like’ structure of the stratum corneum is further compromised. Systemically, a dysfunctional innate and adaptive immune response causes further damage to the epidermis[2].

Pathophysiology

Genetics

Recent studies have established a strong genetic association with atopic dermatitis. Twin studies have indicated high heritability of atopic dermatitis with a concordance rate of 72–86 % for monozygotic twins compared with 21–23 % percent for dizygotic twins.[3]

Genes involved in the pathogenesis of atopic dermatitis include:[4]

  1. Filaggrin Gene mutation:
    • Located on chromosome 1q21 (epidermal differentiation complex) loss-of-function mutations in the filaggrin gene FLG, is strongly associated with a broad range of skin and allergic diseases including atopic dermatitis[5]. Mutation in this gene is also responsible for ichthyosis vulgaris and pachyonychia congenita.[6] The common genetic variant R510X and 2282del4 are very strongly associated with atopic dermatitis.[7]
    • FLG Gene mutation is associated with developing atopic dermatitis at an early age(≤8 years) but is not associated with late childhood or adulthood atopic dermatitis.[8]
  2. SPINK5 and LEKTI gene:
    • Located on chromosome 5q32, Serine Protease Inhibitor Kazal-Type 5 (SPINK5) gene encodes a protease inhibitor Lymphoepithelial Kazal-Type-Related Inhibitor (LEKTI), which is involved in converting profilaggrin into filaggrin and is responsible for marinating the permeability of the normal skin.[9]
    • LEKTI deficiency leads to enhanced cleavage of intercellular attachments, decreased corneocyte cohesion and impaired skin barrier function.[10]
  3. MHC (or HLA) genes
  4. Innate Immune system genes:
    • CARD4 (or NOD1) gene: Caspase recruitment domain–containing protein (CARD) 4
    • CARD15 (or NOD2) gene
    • Monocyte differentiation antigen (or CD14) gene
    • MBL2 gene: mannose-binding lectin (MBL2) gene
    • Toll-like receptor( TLR2, TLR4, TLR6 and TLR 9) genes
    • DEFB1 gene: human β-defensin 1
  5. Adaptive immune system genes
    • Cytokines and related genes:
      • IL-4 gene
      • IL-4Rα gene
      • STAT6 gene (Signal transducer and activator of transcription )
      • IL-10 gene
      • IL-6 gene
      • TNF-α gene
      • TNF-β gene
      • IL-1α gene
      • IL-β gene
      • IFNγ gene
      • IL1RL1
      • IL-5 gene
      • IL-12 β gene
      • IL-12R β
      • IL-13 gene
      • IL-18 gene
      • TGF-β1 gene
      • GM-CSF gene
      • IL-9 gene
      • IL-9R gene
    • Chemokines and related genes:
      • CCL5 gene: Chemokine (C-Cmotif) ligand 5
      • CCL11 gene
      • CCL17 gene
      • CCR3 gene
      • CCR4 gene
      • CMA1 gene: Mast cell chymase 1
    • Drug-metabolizing genes
      • GST genes: glutathione S-transferase
      • NAT-2 gene: N-acetyl transferase
    • Other genes
      • CTLA-4
      • KLK
      • RUNX1 gene
      • IRF2 gene
      • FCER1B gene
      • PHF11 gene

Associated Conditions

Conditions associated with atopic dermatitis include:

  • Atopic triad[11]
    • Atopic dermatitis
    • Allergic rhinitis
    • Asthma
  • Food-induced urticaria/anaphylaxis [12]
  • Ichthyosis vulgaris[13]
  • Ocular comorbidities:
    • Atopic keratoconjunctivitis[14]
    • Vernal keratoconjunctivitis[15]
  • Wiskott-Aldrich syndrome:[16]
    • Thrombocytopenia
    • Eczema (atopic dermatitis)
    • Recurrent infections
  • Hyper-IgE syndrome:[17]
    • Eczema (atopic dermatitis)
    • High serum IgE
    • Recurrent cold abscesses
  • Anemia[18]
  • Psychiatric disorders:[19]
    • Depression[20]
    • Anxiety[21]
    • Suicidal ideations
    • Attention deficit hyperactivity disorder[22]
  • Angina pectoris[23]

Gross Pathology

On gross pathology, erythema, edema, and vesiculation with oozing are characteristic findings of atopic dermatitis while chronic atopic dermatitis is characterized by lichenified plaques with prominent skin markings.[24]

Microscopic Pathology

On microscopic histopathological analysis, characteristic findings of atopic dermatitis include:[25]

  • Acute vesicular lesions:
    • Epidermal psoriasiform hyperplasia
    • Marked intercellular edema with spongiotic vesiculation
    • Marked perivenular infiltrate
    • Epidermal infiltrate, consisting predominately of a lymphohistiocytic infiltrate in the dermis
  • Chronic lichenified plaque:
    • Hyperkeratosis
    • psoriasiform hyperplasia
    • dyskeratosis
    • Marked thickening of the papillary dermis
    • Minimal intercellular edema

References

  1. ↑ Mihm, Martin C; Soter, Nicholas A; Dvorak, Harold F; Austen, K Frank (1976). "The Structure Of Normal Skin And The Morphology Of Atopic Eczema". Journal of Investigative Dermatology. 67 (3): 305–312. doi:10.1111/1523-1747.ep12514346. ISSN 0022-202X.
  2. ↑ Barnes KC (January 2010). "An update on the genetics of atopic dermatitis: scratching the surface in 2009". J. Allergy Clin. Immunol. 125 (1): 16–29.e1–11, quiz 30–1. doi:10.1016/j.jaci.2009.11.008. PMC 2874322. PMID 20109730.
  3. ↑ Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). "Molecular Genetic of Atopic dermatitis: An Update". Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  4. ↑ Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). "Molecular Genetic of Atopic dermatitis: An Update". Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  5. ↑ Irvine AD, McLean WH, Leung DY (October 2011). "Filaggrin mutations associated with skin and allergic diseases". N. Engl. J. Med. 365 (14): 1315–27. doi:10.1056/NEJMra1011040. PMID 21991953.
  6. ↑ Liao H, Waters AJ, Goudie DR, Aitken DA, Graham G, Smith FJ, Lewis-Jones S, McLean WH (December 2007). "Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis". J. Invest. Dermatol. 127 (12): 2795–8. doi:10.1038/sj.jid.5700971. PMID 17657246.
  7. ↑ Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (April 2006). "Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis". Nat. Genet. 38 (4): 441–6. doi:10.1038/ng1767. PMID 16550169.
  8. ↑ Rupnik H, Rijavec M, Korošec P (February 2015). "Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthood". Br. J. Dermatol. 172 (2): 455–61. doi:10.1111/bjd.13477. PMID 25314673.
  9. ↑ Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). "Molecular Genetic of Atopic dermatitis: An Update". Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  10. ↑ Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R (July 2006). "New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions". J. Allergy Clin. Immunol. 118 (1): 3–21, quiz 22–3. doi:10.1016/j.jaci.2006.04.042. PMID 16815133.
  11. ↑ Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ (January 2008). "The prevalence of atopic triad in children with physician-confirmed atopic dermatitis". J. Am. Acad. Dermatol. 58 (1): 68–73. doi:10.1016/j.jaad.2007.06.041. PMID 17692428.
  12. ↑ Eigenmann PA, Calza AM (May 2000). "Diagnosis of IgE-mediated food allergy among Swiss children with atopic dermatitis". Pediatr Allergy Immunol. 11 (2): 95–100. PMID 10893011.
  13. ↑ Bremmer SF, Hanifin JM, Simpson EL (July 2008). "Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: implications for allergic respiratory disease and prognosis". J. Am. Acad. Dermatol. 59 (1): 72–8. doi:10.1016/j.jaad.2008.03.029. PMID 18455261.
  14. ↑ Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC (March 2014). "Atopic keratoconjunctivitis: A review". J. Am. Acad. Dermatol. 70 (3): 569–75. doi:10.1016/j.jaad.2013.10.036. PMID 24342754.
  15. ↑ Pattnaik L, Acharya L (May 2015). "A comprehensive review on vernal keratoconjunctivitis with emphasis on proteomics". Life Sci. 128: 47–54. doi:10.1016/j.lfs.2015.01.040. PMID 25744396.
  16. ↑ Bradley M, Söderhäll C, Wahlgren CF, Luthman H, Nordenskjöld M, Kockum I (2001). "The Wiskott-Aldrich syndrome gene as a candidate gene for atopic dermatitis". Acta Derm. Venereol. 81 (5): 340–2. PMID 11800140.
  17. ↑ Ohameje NU, Loveless JW, Saini SS (2006). "Atopic dermatitis or hyper-IgE syndrome?". Allergy Asthma Proc. 27 (3): 289–91. PMID 16913276.
  18. ↑ Drury KE, Schaeffer M, Silverberg JI (January 2016). "Association Between Atopic Disease and Anemia in US Children". JAMA Pediatr. 170 (1): 29–34. doi:10.1001/jamapediatrics.2015.3065. PMID 26619045.
  19. ↑ Rønnstad A, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP (September 2018). "Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis". J. Am. Acad. Dermatol. 79 (3): 448–456.e30. doi:10.1016/j.jaad.2018.03.017. PMID 30119868. Vancouver style error: initials (help)
  20. ↑ Bao Q, Chen L, Lu Z, Ma Y, Guo L, Zhang S, Huang X, Xu S, Ruan L (October 2018). "Association between eczema and risk of depression: A systematic review and meta-analysis of 188,495 participants". J Affect Disord. 238: 458–464. doi:10.1016/j.jad.2018.05.007. PMID 29929155.
  21. ↑ Cheng CM, Hsu JW, Huang KL, Bai YM, Su TP, Li CT, Yang AC, Chang WH, Chen TJ, Tsai SJ, Chen MH (June 2015). "Risk of developing major depressive disorder and anxiety disorders among adolescents and adults with atopic dermatitis: a nationwide longitudinal study". J Affect Disord. 178: 60–5. doi:10.1016/j.jad.2015.02.025. PMID 25795537.
  22. ↑ Strom MA, Fishbein AB, Paller AS, Silverberg JI (November 2016). "Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults". Br. J. Dermatol. 175 (5): 920–929. doi:10.1111/bjd.14697. PMC 5216180. PMID 27105659.
  23. ↑ Thyssen JP, Halling-Overgaard AS, Andersen Y, Gislason G, Skov L, Egeberg A (June 2018). "The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis". Br. J. Dermatol. 178 (6): 1272–1279. doi:10.1111/bjd.16215. PMID 29210061. Vancouver style error: initials (help)
  24. ↑ Mihm, Martin C; Soter, Nicholas A; Dvorak, Harold F; Austen, K Frank (1976). "The Structure Of Normal Skin And The Morphology Of Atopic Eczema". Journal of Investigative Dermatology. 67 (3): 305–312. doi:10.1111/1523-1747.ep12514346. ISSN 0022-202X.
  25. ↑ Mihm, Martin C; Soter, Nicholas A; Dvorak, Harold F; Austen, K Frank (1976). "The Structure Of Normal Skin And The Morphology Of Atopic Eczema". Journal of Investigative Dermatology. 67 (3): 305–312. doi:10.1111/1523-1747.ep12514346. ISSN 0022-202X.

Template:WH Template:WS

Causes

Differentiating Atopic Dermatitis from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other diagnostic studies

Treatment

Medical therapy | Primary prevention | Secondary prevention | Financial costs | Future therapies

Case Studies

Case #1

Related Chapters

External Links


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Atopic_dermatitis&oldid=1496157"